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Background: To describe the main imaging characteristics of pancreatic metastases from renal cell carcinoma
(RCC) with particular attention to CT features, underlining possible criteria for a differential diagnosis.
Methods: 15 patients have been included in this study. 14 patients underwent multislice CT with triphasic
acquisition (unenhanced, pancreatic parenchymal and portal venous phases). In 9 cases a delayed phase (120 sec)
was also acquired. 5 patients underwent MRI, before and after administration of gadolinium.
Results: The mean time interval between nephrectomy and recurrence was 7.5 years (range 1-17 years). On CT
metastases avidly enhanced in the parenchymal phase and then demonstrated a significant wash-out, approaching
isodensity to the normal pancreatic parenchyma in the portal phase. In the portal phase 20 of the 25 lesions found
in the arterial phase were recognizable. On non-enhanced scans, only 13 of the 25 lesions were detected.
On MRI, with the limitations due to the paucity of cases, the metastatic foci appeared hypointense to normal
pancreatic tissue on T1-weighted images, and hyperintense on T2- and diffusion-weighted images. After
gadolinium, the behaviour was similar to that reported for CT, except for one patient in whom two metastatic foci
presented a signal intensity almost isointense to the surrounding parenchyma, accompanied also by an unusual
lowering of the signal on DWI (diffusion-weighted imaging) with high b-values. Compared to CT, with MRI the
lesions appeared all detectable even on non-enhanced acquisitions.
Conclusion: Renal Cell Carcinomas require a prolonged CT or MRI follow-up.
In patients with RCC history, an early arterial or a pancreatic parenchymal phase is always mandatory, as pancreatic
metastases typically present themselves as hypervascular lesions. This behavior is similar to that of neuroendocrine
tumors, while the other primary pancreatic tumors tend to be hypovascular.
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Metastatic lesions in the pancreas are uncommon and ac-
count for 2% to 5% of all pancreatic malignancies [1-3].
However, pancreas is a possible site for metastases from
renal cell carcinoma (RCC), not unfrequently being the
only metastatic site [4].
Very delayed metastases, i.e. later than ten years
after tumor nephrectomy, occur in more than 10% of
patients [5].
Metastases are only rarely symptomatic in the early
phases, with symptoms including abdominal pain, back* Correspondence: vinci.teo@gmail.com
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unless otherwise stated.pain, gastrointestinal bleeding due to duodenal infiltration,
obstructive jaundice, weight loss, pancreatitis, and diabetes.
Retrospective series showed that when there is no evi-
dence of metastatic spread in other organs, pancreatic
metastatic lesions from RCC are a favorable indication
for a radical surgery, offering good chances of long-term
survival [6-8]. In a recent study Karam JA et al. reported
that metastasectomy is feasible with acceptable morbid-
ity in a cohort of select patients with a limited tumor
burden after targeted therapy [9]. Moreover, it has been
demonstrated that tumor burden characteristics are as-
sociated with clinical outcome in patients with metasta-
sis from RCC treated with vascular endothelial growth
factor-targeted therapy such as sunitinib [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with a history of RCC should be monitored in order to
detect early recurrences. Efficacy and modalities of post-
operative radiological follow-up are still debated.
In this article, we describe the main imaging features
of pancreatic metastases from RCC on the basis of a retro-
spective review of fifteen cases from our archives and a re-
view of the literature.Methods
A retrospective search for patients with a diagnosis of pan-
creatic metastases from RCC obtained between February
2004 and June 2010 at the University Hospital of Padova
was performed.
Fifteen cases were identified and their clinical records
reviewed. Diagnosis was based on medical history, im-
aging and histological examination of surgical specimens.
The group of patients comprised six women and
nine men, aged between 39 and 82, with a mean age
of 63.5 years.
Fourteen out of fifteen patients underwent multislice
CT, using 16- and 64-slice scanners (Emotion 16 and
Somatom Sensation 64; Siemens, Erlangen, Germany).
An initial non-enhanced acquisition was performed,
followed by a breath-hold pancreatic parenchymal phase
acquisition at 30-40 sec after injection and a portal venous
phase scan, obtained 60–70 seconds after injection. In 9
cases a delayed phase of 120 sec was also acquired, even if
for purposes different from the characterization of the
pancreatic tumor. The intravenous administration of 150-






1 2 10/18 Head/Body Isodense 1 Hyper
2 2 16/22 Head/Body Hypodense 1 Hyper
3 1 40 Head Hypodense 1 Hyper
4 2 17/11 Head/Body Isodense 2 Hyper
5 1 10 Body Hypodense 1 Hyper
6 3 10/5/5 Head/Body/Tail Hypodense 1 Hyper
7 2 16/8 Body/Tail Isodense 1 Hyper/Is
8 1 10 Tail Isodense 0 Hyper
9 3 12/8/5 Head/Body/Tail Hypodense 1 Hyper/Is
11 1 7 Body Hypodense 0 Hyper
12 1 39 Tail Hypodense 1 Hyper
13 2 16/10 Body/Tail Hypodense 1 Hyper
14 1 20 Body Isodense 1 Hyper
15 3 10/45/6 Head/Body/Tail Hypodense 1 Hyper/Is
Sum 25 13GE Healthcare – USA) was given using an automatic in-
jector at a rate of 3.5-5 mL/sec.
Four-millimeter axial images, as well as coronal and
sagittal reformatted images, were sent to the picture ar-
chiving and communication system.
Five patients underwent an abdominal 1.5 Tesla MRI
scan (Magnetom Espree, Siemens, Erlangen, Germany)
(one only MRI, four CT plus MRI) before and after i.v
administration of gadolinium. Our protocol included
axial GRE T1 in-phase/out-of-phase images (TR of
129 ms, TE respectively of 4.87 and 2.38 ms; field of
view 380 mm; slice thick-ness, 4 mm), TSE T2 weighted
images (TR, 3700 ms; TE, 92 ms; field of view 380 mm;
slice thick-ness, 4 mm), axial and coronal HASTE T2-
weighed images with and without fat saturation (TR,
1500 ms; TE, 90 ms; field of view, 380 mm; slice thick-
ness, 4-6 mm), and diffusion-weighted (b 50-400-800 s/
mm2) images.
After administration of contrast agent axial GRE T1-
weighted images (TR, 5.07 ms; TE, 2.38 ms, field of view
400 mm; slice thick-ness, 4 mm) were obtained at 30, 70
and 120 seconds.
Images were evaluated by three radiologists.
Fourteen patients underwent surgery, while in one pa-
tient the diagnosis was autoptical. Both typical resections
(pancreatoduodenectomy, distal splenopancreatectomy,
total pancreatectomy) and atypical resections (enucleation,
middle pancreatectomy, spleen-preserving distal pancrea-
tectomy) were performed. Histological examination of the
resected specimens showed metastases from renal cell car-
cinoma in all of these cases. All patients were treated ac-
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to conduct a retrospective review of the patients’ medical
and imaging records.Results
A total of 26 metastatic lesions were identified in 15 pa-
tients: 19 lesions were detected with CT, 1 with MRI
and 6 with both CT and MRI (Tables 1 and 2).
Disease-free time interval between primary treatment
and recurrence ranged from 1 to 17 years (mean 7.5 years).
In 11 patients the pancreas was the only metastatic
site. 3 patients also presented with lung metastases, in
one case associated with liver metastases. 1 patient had a
concomitant thyroid metastatic lesion.
Solitary lesions were found in 7 patients (Figure 1), while
8 patients presented with multiple metastases (Figure 2).
The lesions were distributed throughout the pancreas
without notable predilection for a particular part of the
gland. No patients presented a diffuse involvement of the
pancreas.
The metastatic foci usually appeared well-defined, often
with discrete margins. 21 were round or ovoid with
smooth borders, 5 were lobular. They ranged in size from
0.7 cm to 4.0 cm (median diameter was 1.5 cm).
In 2 patients there was evident obstruction of the main
pancreatic duct with dilatation of the duct upstream from
the obstruction. 4 cases presented biliary tree dilatation.
No patients demonstrated involvement of a neighbour-
ing extra-pancreatic artery; even if venous involvement
is often more difficult to assess, in our series the super-
ior mesenteric and portal veins appeared unaffected.
On contrast-enhanced CT, metastases avidly enhanced
in the arterial or pancreatic parenchymal phase and dem-
onstrated a significant wash-out on portal and delayed
phase images, performed after 120 seconds (Figure 3).
Nodules smaller than 2-2.5 cm in diameter showed
homogeneous enhancement, while larger masses had anFigure 1 Solitary lesions. Two examples of solitary spherical tumors of th
(B) images, with the typical appearance of a predominantly solid, well-defiheterogeneous enhancement, with central hypodense
areas probably due to necrosis.
On MRI, the lesions showed signal intensity lower than
normal pancreatic tissue on pre-contrast T1-weighted
images, both on in-phase and out-of-phase acquisitions
(Figure 4). They conversely presented an heterogeneous
or moderately hyperintense signal on T2-weighted im-
ages with or without fat-saturation, including diffusion-
weighted sequences.
After the administration of gadolinium, nodules smaller
than 2-2.5 cm in diameter showed homogeneous enhance-
ment, while larger masses presented heterogeneous en-
hancement with central hypodense areas, probably due to
internal necrosis.
Only in 1 patient we found two metastatic foci that re-
sulted almost isointense to the surrounding pancreatic
parenchyma, from which they were separated by a thin
hypointense rim. These lesions also showed loss of signal
intensity on DWI with high b-values, while the other le-
sions in our series showed increased signal intensity with
higher b-values (Figure 5).Discussion
Metastases from renal cell carcinoma (RCC) may be
found at the time of primary tumour diagnosis or, more
frequently, during follow-up after surgery [5,7,11]. A re-
port showed that approximately 10% of 10-year survi-
vors after tumor nephrectomy had late recurrences
from RCC [5].
Nevertheless, pancreatic metastases from RCC are un-
usual. In autopsy series of patients with RCC, the re-
ported incidence ranged from 1 to 3% [12].
If pancreatic metastases are discovered at the follow-
up, pancreas not unfrequently is the only metastatic site
and relatively often has a solitary metastasis. In fact,
RCC has been reported to be the most common primary
tumor leading to solitary pancreatic metastasis [13]. Noe pancreatic tail, respectively on contrast-enhanced CT (A) and MRI
ned mass with smooth borders.
Figure 2 Multiple lesions. An arterial phase acquisition on CT
shows two synchronous metastases as inhomogeneously enhancing
nodular masses in the pancreatic body and tail.
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isolated pancreatic metastasis and the site of the primary
renal cell carcinoma [14].
However, multifocality of pancreatic metastases from
RCC is not unusual, ranging from 20% to 45% [3,15]. ItFigure 3 Vascularity pattern. Axial CT scans obtained unenhanced (A) an
enhancement show a large, solitary round metastasis of the pancreatic hea
in portal and delayed phases.does not necessarily relate to a worse outcome and it
does not represent a contraindication to surgery.
Despite the uni- or multifocality, when there are no
detectable metastases in other organs there is a favorable
indication for a radical surgery, with a reported mean
survival of 4 years [3]. In fact surgery is considered the
gold standard therapy for localized disease.
In addition, the introduction of targeted therapy, in-
cluding inhibitors of vascular endothelial growth factor
(VEGF) and mammalian target of rapamycin (mTOR),
has dramatically changed the outcome of patients with
metastatic renal cell cancer, which was typically a che-
moresistant disease [16].
For all these reasons, it is crucial to achieve an early
radiological diagnosis of recurrence.
In our series, both on CT and MRI the metastatic foci
appeared as round or ovoid masses, mostly well-delineated
and with smooth borders.
As reported in the literature, metastases resulted iso-
dense or hypodense in comparison to normal parenchyma
on unenhanced CT, avidly enhanced in the pancreatic late
arterial phase and demonstrated a significant wash-out, in
particular on delayed phase images.
In the delayed phase lesions appeared sometimes hard
to recognize, approaching isodensity with the surroundingd during arterial (B), portal (C) and delayed (D) phases of contrast
d. Note that lesion is best seen in the arterial phase and less well seen
Figure 4 In-phase, out-of-phase and diffusion-weighted images. Lesions with signal intensity lower than normal pancreatic tissue on
in-phase (A) and out-of-phase images (B). They showed hyperintense signal on T2-weighted (C) and diffusion-weighted sequences obtained
at b values of 400 (D).
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therefore mandatory whenever we are dealing with a pa-
tient with history of RCC, whatever the clinical indication
for imaging [2,4,12].
Upon our knowledge, there are few reports in the lit-
erature concerning MRI imaging features of pancreatic
metastases from RCC.
In our experience, metastases showed low signal in-
tensity compared with the normal pancreatic tissue on
pre-contrast T1-weighted images, and moderately hy-
perintense signal on T2- and T2 fat-sat images. Lesions
larger than 2 cm often had heterogeneous signal both on
T1- and T2-weighted sequences, due to necrosis [17].
After the administration of gadolinium, metastases pre-
sented enhancement features similar to those described
with CT. An early and homogeneous enhancement was
usually seen in smaller metastases, while larger lesions
showed a thick rim of enhancement.
In one patient, two intrapancreatic lesions appeared al-
most isointense to the surrounding pancreatic parenchyma
on dynamic contrast enhanced MRI. This behavior, per-
haps, might be related to a higher necrotic content of the
lesions, as suggested also by the lowering of their signal
intensity on DWI acquisitions with the increasing of the b-
values, while the other metastatic lesions in our series
showed a persistent elevated signal.The non-enhanced features described above, and the
early enhancement after contrast medium injection with
both CT and MRI are characteristics that can also be found
in the presence of endocrine pancreatic tumors, while pri-
mary adenocarcinomas tend to be hypovascular [18].
It is really hard to differentiate RCC metastases from
endocrine tumors of the pancreas.
Symptoms of pancreatic metastases such as abdominal
pain, jaundice, weight loss, and steatorrhea may be caused
by tumoral invasion of the choledochus or main pancre-
atic duct (Figure 6). Pancreatic endocrine tumors usually
do not invade these structures: this could help in the dif-
ferentiation between pancreatic metastasis from RCC and
endocrine tumor [7,19].
Moreover, a pancreatic endocrine tumor will cause
endocrine symptoms if it is a functional tumor.
Even if octreotide or somatostatin receptor scintig-
raphy is helpful in the identification of neuroendocrine
tumors, some metastatic lesions may also express som-
atostatin receptors, showing an intense uptake of octreo-
tide at scintigraphy [20]. This should be kept in mind as
it could mislead the diagnosis. On the other hand, it
might result useful for therapeutic purposes.
Concerning primary adenocarcinomas of the pancreas,
the fundamental clue for the differential diagnosis with
RCC metastases consists in the pattern of enhancement
Figure 5 Arterial phase and diffusion-weighted images. Lesions almost isointense to the surrounding pancreatic parenchyma on arterial
phase acquisition, circumscribed by a thin hypointense rim (A). They show lower signal intensity on DWI sequences with the increasing of
b-values (B, C, D).
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cality within the pancreas, relatively common in the
presence of recurrence, is not characteristic of primary
pancreatic carcinoma.
Another point of differentiation could be the evidence
of encasement or infiltration of the peripancreatic arteries
and veins. In our series no patients with metastases from
RCC showed involvement of these structures.
However, the clinical history remains always the first
thing to consider. An hypervascular pancreatic tumor in
a patient with a previously diagnosed renal cancer shouldFigure 6 Obstruction of the common bile duct with upstream dilatati
duct (B).be considered a metastasis from renal cancer until proven
otherwise.
Conclusion
Pancreatic metastases may present many years after the
resection of the primary renal cell carcinoma.
An early arterial phase or a pancreatic parenchymal
phase are mandatory both on CT and MRI for patients
with a history of RCC, despite the reason why the pa-
tient is undergoing the exam or the time passed after
surgery.on of the biliary tree (A); distal dilatation of the main pancreatic
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creatic tumors are the most challenging ones, as the other
primary pancreatic tumors tend to be hypovascular.
However, clinical history remains extremely helpful. A
hypervascular pancreatic tumor in a patient with a his-
tory of renal cancer should be considered a metastasis
from renal cancer until proven otherwise.
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